CRISPR Therapeutics shareholders elect new director, approve board size increase at 2025 AGM

CRISPR Therapeutics AG

New director Briggs W. Morrison, M.D. elected; board size maximum increased.
Binding votes on executive compensation approved with significant against votes (e.g., equity grant for execs: 31.8M for, 9.0M against).
Non-binding advisory vote on named executive officer compensation passed with 29.1M for vs 11.7M against.
Shareholders approved amendments to articles of association, effective June 6, 2025, subject to Swiss registration.
All director nominees re-elected; auditors Ernst & Young re-elected for FY2025.

item 5.03item 5.07item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.